|  |  |  |  |
| --- | --- | --- | --- |
| **Effects of lin-glycine on cardiac ion channels** | | | |
| **Effects of lin-glycine at 0.2 μM** | | | |
| Channel Name | I/I0 (0.2 μM) | ΔV0.5 (mV) (0.2 μM) | Gmax/G­max0 (0.2 μM) |
| Kv7.1/KCNE1 | 1.2± 0.1 | -2.7 ± 1.5 | 1.2 ± 0.1 |
| Cav1.2 | 0.9 ± 0.1 | 0.1 ± 1.7 | 1.1 ± 0.03 |
| Nav1.5 | 1.0 ± 0.03 | -0.2 ± 0.06 | 1.0 ± 0.03 |
| **Effects of lin-glycine at 0.7 μM** | | | |
| Channel Name | I/I0 (0.7 μM) | ΔV0.5 (mV) (0.7 μM) | Gmax/G­max0 (0.7 μM) |
| Kv7.1/KCNE1 | 1.4 ± 0.1 | -3.3 ± 3.0 | 1.3 ± 0.1 |
| Cav1.2 | 0.9 ± 0.1 | -0.7 ± 1.8 | 1.1 ± 0.04 |
| Nav1.5 | 1.0 ± 0.04 | -1.2 ± 0.3 | 1.0 ± 0.05 |
| **Effects of lin-glycine at 2 μM** | | | |
| Channel Name | I/I0 (2 μM) | ΔV0.5 (mV) (2 μM) | Gmax/G­max0 (2 μM) |
| Kv7.1/KCNE1 | 2.5 ± 0.4 | -10.0 ± 2.8 | 1.8 ± 0.2 |
| Cav1.2 | 0.9 ± 0.1 | -2.9 ± 1.4 | 1.2 ± 0.1 |
| Nav1.5 | 0.9 ± 0.1 | -4.3 ± 0.8 | 0.9 ± 0.06 |
| **Effects of lin-glycine at 7 μM** | | | |
| Channel Name | I/I0 (7 μM) | ΔV0.5 (mV) (7 μM) | Gmax/G­max0 (7 μM) |
| Kv7.1/KCNE1 | 5.1 ± 0.4 | -23.8 ± 1.6 | 2.3 ± 0.2 |
| Cav1.2 | 0.8 ± 0.1 | -3.0 ± 1.6 | 1.0 ± 0.1 |
| Nav1.5 | 0.5 ± 0.1 | -15.2 ± 2.8 | 0.5 ± 0.1 |
| **Effects of lin-glycine at 20 μM** | | | |
| Channel Name | I/I0 (20 μM) | ΔV0.5 (mV) (20 μM) | Gmax/G­max0 (20 μM) |
| Kv7.1/KCNE1 | 5.3 ± 0.5 | -26.4 ± 4.4 | 2.4 ± 0.2 |
| Cav1.2 | 0.7 ± 0.1 | -3.7 ± 1.5 | 1.0 ± 0.1 |
| Nav1.5 | 0.3 ± 0.02 | -21.7 ± 1.2 | 0.2 ± 0.02 |
| Table containing source data for the application of the PUFA analogue lin-glycine on the cardiac Kv7.1/KCNE1, Cav1.2, and Nav1.5 channels at every concentration (0.2, 0.7, 2, 7, and 20 μM). Data represented as (mean ± SEM). | | | |